Headache and Migraine

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.

The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.

The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.

Oral CGRP inhibitor atogepant significantly reduced monthly headache days and improved daily function in adults with 4 to 14 headaches per month.

A neurologist and a rheumatologist sat down with Patient Care editors to talk about their focus on balance in the gut microbiome as an essential element of clinical care.

A woman in her 50s who has a history of tension headache presents to the ED with a headache different from any she has had. Mild photophobia is the only finding on physical exam. Your dx?

The uptake among primary care physicians of new migraine drugs has been hindered by 2 significant obstacles, a headache specialist explained to Patient Care Online.

Headache specialist Peter McAllister, MD, discusses how the new migraine medications differ from existing therapies.

New and highly specific migraine drugs have significantly changed the clinical landscape for patients. We talked with Peter McAllister, MD, about where the research goes next.

Authors of 2 large cannabis-user database analyses discuss the possible reasons for observed dose increase over time by individuals using inhaled cannabis for pain relief.